Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02827838 · ClinicalTrials.gov registry record · Early Phase 1
Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer
A Early Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
NCT02827838 is a Early Phase 1 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 17 participants.
The verdict
NCT02827838, a Early Phase 1 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This pilot clinical trial studies how well durvalumab before surgery works in treating patients with oral cavity or oropharynx cancer. Monoclonal antibodies, such as durvalumab, may interfere with the ability of tumor cells to grow and spread.
Interventions
- BIOLOGICAL Durvalumab
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Therapeutic Conventional Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-01 |
| Est. Completion | 2022-04-22 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02827838
The ClinicalTrials.gov registry entry for NCT02827838 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Durvalumab is the first listed.
NCT02827838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02827838 about?
NCT02827838 is a clinical study titled "Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer". This pilot clinical trial studies how well durvalumab before surgery works in treating patients with oral cavity or oropharynx cancer. Monoclonal antibodies, such as durvalumab, may interfere with the ability of tumor cells to grow and spread.
What is the current status of trial NCT02827838?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2017-01. Estimated completion is 2022-04-22.
What interventions are being tested in trial NCT02827838?
The interventions under investigation include: Durvalumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Therapeutic Conventional Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT02827838?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.